Board of Directors

Pharmaero’s Board of Directors holds to the responsibility to determine and oversee the Company’s overall strategy as well as in contributing to developing the Company as a focused, sustainable, global pharmaceutical device company. Mats Persson, Chairman of the Board & Senior Advisor, SHL Group Mats has held various positions within SHL Group since joined as […]

Read more

Management

Mats Persson, Managing Director Mats was appointed Managing Director at Pharmaero in September 2018. He has vast experience from global pharmaceutical companies, having held positions at Glaxo, Upjohn and Pharmacia & Upjohn, and being part owner of SHL Group since 2000. Mats also holds a Senior Advisor position at SHL. Within the inhalation segment, Mats has […]

Read more

Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience, Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing […]

Read more

About Pharmaero

Pharmaero ApS is a 50:50 joint venture between Scandinavian Health Ltd. (SHL Group), a significant player in the injectable device space, and Xellia Pharmaceuticals a prominent Active Pharmaceutical Ingredients and Finish Dosage Form supplier. Pharmaero develop products based on the novel Aqueous Droplet Inhaler; the ADI. The two first products provides anti-infective treatments localized to the lung and respiratory tract […]

Read more

top